Fact sheet: Aviva AXA Fram Biotech Pn

Fund information
Fund name
Aviva AXA Framlington Biotech Pn S6
Fund manager company
Aviva Life & Pensions UK Ltd
Fund type
Pension Fund
Fund managers
  • Deane Donnigansince 31/03/2010
Underlying fund
AXA Framlington Biotech
Fund objective
To provide long-term capital appreciation by investing principally in equity securities of companies in the biotechnology, genomic and medical research industries worldwide.
Benchmark
  • NASDAQ Biotechnology
Investment style
No data available.
Investment method
No data available.
Quick stats
1 Year return
-2.1%
1 Year rank in sector
469/514
Sector
PN Specialist
Yield
-
Fund size
£32m (£38m last year)
FE Risk score
?FE Risk Scores measure the riskiness of instruments relative to the FTSE 100 index of shares. Weekly volatility is measured over three years with recent behaviour counting more heavily than earlier behaviour. Cash-type investments will have scores close to zero. Funds will tend to have scores in the 0-150 range. The FTSE 100 is always scored at 100. There is no upper limit.
219
Bid price
505.12
Top in this sector
Fund name1 Year
OMW Neptune Rus + Grtr Rus48.9%
ReAssure AL NptRu&GtrRus Pn48.8%
L&G Nep Russia&Gtr Russia Pn48.2%
OMW InvescoPerpetualEmgEurpn44.4%
Scot Eq JPM Emg Eur Eq Pn43.8%
...more in PN Specialist

Performance snapshot

Holdings snapshot

  • USA84.2%
    UK3.1%
    Switzerland3.1%
    France2.4%
    Belgium2.4%
  • Biotechnology/Medical79.1%
    Pharmaceuticals13.5%
    Technology3.6%
    Money Market1.8%
    Electronic & Electrical Equipment1.2%
  • US Equities84.2%
    UK Equities3.1%
    Swiss Equities3.1%
    French Equities2.4%
    Belgian Equities2.4%

Performance vs Sector

Cumulative performance
 1 mth3 mth6 mth1 yr3 yr5 yr
Fund4.8%1%9.1%-2.1%60.1%240%
Sector-0%-0.1%6.8%9.4%21.6%42.3%
Rank within sector15 / 546156 / 545177 / 531469 / 51412 / 3861 / 317
Quartile1st2nd2nd4th1st1st
Calendar performance
 YTD - 20162015201420132012
Fund-6.1%12.5%48.6%64.4%26.3%
Sector9.3%2%7.2%11%7.7%
Rank within sector502 / 51411 / 4502 / 3882 / 3572 / 318
Quartile4th1st1st1st1st
Risk statistics
Alpha
?Alpha is a measure of a fund's over- or under-performance by comparison to its benchmark. If the Alpha is 5, the fund has outperformed its benchmark by 5%; so the greater the Alpha, the greater the outperformance.
3.08
Beta
?Beta estimates a fund's volatility by comparison to that of its benchmark. A fund with a beta close to 1 means that the fund will move generally in line with the benchmark. Higher than 1 and the fund is more volatile than the benchmark and vice versa.
2.67
Sharpe
?This commonly-used measure calculates the level of return over and above the return of a notional risk-free investment, such as cash. The difference in returns is then divided by the fund's volatility. The resulting ratio is an indication of the amount of excess return generated per unit of risk.
0.55
Volatility
?Volatility (or standard deviation), when applied to an investment fund, expresses its risk. It shows how widely a range of returns varied from the fund's average return over a particular period. For example, if a fund had an average return of 5%, and its volatility was 15, this would mean that the range of its returns over the period had swung between +20% and -10%.
26.09
Tracking error
?This measures the standard deviation of a fund's excess returns over the returns of an index or benchmark portfolio. As such, it can be an indication of 'riskiness' in the manager's investment style. A Tracking Error below 2 suggests a passive approach. At 3 and above the the manager will be deploying a more active investment style.
22.98
Information ratio
?This is a useful risk-adjusted measure of actively managed fund performance. It is calculated by deducting the returns of the fund's benchmark from the fund's overall returns, then dividing the result by its tracking error. The higher the Information Ratio the better. It is generally considered that a figure of 0.5 reflects a good performance, 0.75 very good, and 1.00 outstanding.
0.47
R-Squared
?An indication of how closely correlated a fund is to an index or a benchmark. Values for R-Squared range between 0 and 1, with 0 indicating no correlation at all and 1 showing a perfect match. Values upwards of 0.7 suggest that the fund's behaviour is increasingly linked to its benchmark.
0.37
Price movement
52 week high543.69
52 week low389.13
Current bid price505.12
Current offer price-
Current mid price-
Region
1USA84.18%
2UK3.11%
3Switzerland3.08%
4France2.41%
5Belgium2.35%
6Sweden2.17%
7Money Market1.82%
8Germany0.49%
9Canada0.39%
Industry sector
1Biotechnology/Medical79.07%
2Pharmaceuticals13.5%
3Technology3.62%
4Money Market1.82%
5Electronic & Electrical Equipment1.22%
6Health Care0.77%
Asset type
1US Equities84.18%
2UK Equities3.11%
3Swiss Equities3.08%
4French Equities2.41%
5Belgian Equities2.35%
6Swedish Equities2.17%
7Money Market1.82%
8German Equities0.49%
9Canadian Equities0.39%
Individual holdings
1GILEAD SCIENCES INC9.8%
2BIOGEN INC9%
3CELGENE CORP8.6%
4ALEXION PHARMACEUTICALS INC7.7%
5VERTEX PHARMACEUTICAL5.3%
6REGENERON PHARMACEUTICALS INC4.8%
7INCYTE CORP4.6%
8AMGEN INC4.5%
9BIOMARIN PHARMACEUTICAL3.6%
Management
Fund manager group
Aviva
Fund manager company
Aviva Life & Pensions UK Ltd
Fund type
Pension Fund
Fund objective
To provide long-term capital appreciation by investing principally in equity securities of companies in the biotechnology, genomic and medical research industries worldwide.
Benchmark
  • NASDAQ Biotechnology
Investment style
No data available.
Investment method
No data available.
Fund managers
NameSinceBiography
Deane Donnigan31/03/2010Deane joined AXA Framlington in October 1997. She currently manages the AXA Framlington Health Fund and AXA Framlington Biotech Fund. Deane attended University of Georgia and the Medical College of Georgia, spending seven years working as a pharmacy intern and a registered pharmacist while working on her BS and PharmD degrees. After this, she worked for 2 years at the Medical College of Georgia Hospital and Clinics with paediatric and adult patients. In 1990, Deane accepted a position with Emory University Hospital, Atlanta, Georgia, as a clinical specialist.
Compliance
No data available.
Domicile
No data available.
Fund for sale in
United Kingdom
Aviva AXA Framlington Biotech Pn Inet
Initial charge-
Annual charge0.6%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price447.77
CurrencyGBX
Price updated08/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeBEI2
Aviva AXA Framlington Biotech Pn S6
Initial charge-
Annual charge0.6%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)-
Bid price505.12
Offer price-
Mid price-
CurrencyGBX
Price updated08/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeBEI1
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Moneywise and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.